Centogene's Rare Disease Database Hits One Billion Collected Alleles


Centogene’s global mutation database for rare genetic disorders, CentoMD, has reached a milestone of more than one billion collected alleles from over 200,000 patient samples.

“CentoMD provides a virtual encyclopedia of genetic information, allowing healthcare professionals to diagnose and treat rare diseases in a much more efficient, speedy and targeted manner,” Arndt Rolfs, MD, CEO of Centogene, explained.

The company believes that the research available within the database can assist healthcare professionals in diagnosing their patients efficiently, resulting in more effective treatments.

“While any given rare disease affects only a small percentage of people, more than 350 million people worldwide are suffering from rare diseases. Diagnosing a patient with a rare disease can be exceedingly complex and challenging as our ability to discover a genetic variation in a patient genome is ahead of our ability to interpret that variation,” said Prof Rolfs in a press release.

“Reaching over one billion alleles in our database CentoMD is a tremendous milestone and will significantly improve the quality of any genetic data set, being the basis for further medical care.”

The data within CentoMD are based on clinically diagnosed individuals worldwide, and include information on rare diseases regarding genetic location, protein changes, types of variation, and biochemical analyses.

Healthcare professionals have access to standardized annotated genetic mutations and 57% of unpublished clinical variants with CentoMD. Subscribers can export relevant data to an excel file for their own personal records.

The most updated CentoMD database gives clinicians access to over 5.2 million variants, with many variants detected by whole exome sequencing.

Clinicians are also able to perform symptoms-based queries based on Human Phenotype Ontology (HPO), and in return CentoMD provides potential candidate genes and variants that can possibly define the symptoms of interest.

CentoMD is updated on a quarterly basis while a constant reevaluation of variants is carried out by Centogene. Approximately 18,000 cases are diagnosed each month and are added to the database. Healthcare professionals subscribed to the database are always notified of these changes to ensure they are giving the most accurate diagnosis for their patients.

Centogene believes that the motivation for researchers who research rare genetic diseases is based on a patient-centric attitude.

“Supported with this information, healthcare providers and pharmaceutical partners will be able to determine the most accurate diagnosis and ultimately, help close the gap between diagnosis and therapy,” Rolfs concluded.

Related Videos
How Gene and Cell Therapy Is Developing in Dermatology
Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.
The Prospect of Pz-cel in RDEB Treatment, with Peter Marinkovich, MD
Comparing New Therapies for Dystrophic Epidermolysis Bullosa
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Dunia Hatabah, MD | Image Credit: HCPLive
Ricky Safer: What Clinicians Need to Know About PSC
Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome
Saeed Mohammad, MD: IBAT Inhibitors for Cholestatic Disease
Mercedes Martinez, MD: Treatment Strategies for Autoimmune Hepatitis
© 2024 MJH Life Sciences

All rights reserved.